High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities
Results suggest a need for more effective antiepileptic treatments
EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591].
This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy Program at the University of Leuven Hospitals, in cooperation with the Dravet Syndrome European Federation, a federation of European Dravet syndrome patient organizations aiming to improve the quality of life of patients and caregivers. Zogenix provided financial support for the study.
Dravet syndrome is a rare form of intractable (treatment-resistant) epilepsy that begins in infancy and is associated with potentially life-threatening, frequent and severe seizures, developmental delay, cognitive impairment and an elevated risk of sudden unexplained death in epilepsy (SUDEP).1 The wide scope of comorbidities associated with this condition, combined with it being a rare disease, can be expected to result in a high impact on caregivers, affecting all aspects of their lives.2
"Children and Adults with Dravet syndrome face a diminished quality of life due to the debilitating number of seizures they experience, as well as the associated developmental issues. The prognosis for these children is poor as current treatment options are limited and often fail to provide adequate seizure control," said Isabella Bambrilla, chairman of the Dravet Syndrome European Federation. "These results from the DISCUSS survey allow us to gain a deeper understanding of seizure burden for patients with Dravet syndrome and the disease's impact on quality of life for patients and their families."
Survey findings reveal that, despite broadly following current treatment guidelines, less than 10 percent of patients with Dravet syndrome were seizure free in the previous three months. Additionally, half of the patients required at least one emergency admission and 46 percent at least one ambulance call in the previous 12 months.
With regards to associated comorbidities, nearly all (99.6 percent) patients aged 5 years or older experienced at least one or more motor, speech, learning, or behavioral impairment. Of that group, 74 percent experienced motor impairment, 80 percent experienced speech impairment, 98 percent experienced learning difficulties, 42 percent were diagnosed with autism, 24 percent were diagnosed with ADHD, and 51 percent experienced other behavioral difficulties. On average, patients aged 5 years or older had four of the six surveyed impairments or comorbidities. Of interest, 13 percent of all patients older than 5 years of age were reported as not speaking at all.
Results from the survey also suggest that physician awareness of Dravet syndrome has markedly improved over time. Doctors immediately recognized Dravet syndrome in 45 percent of preschool children versus only 12 percent of adult patients. Overall, there were no clear differences in disease characteristics for patients when looking at the length of time to diagnosis, but early diagnosis is associated with earlier access to appropriate drug therapy and earlier access to specialized rehabilitation programs.
"As a physician who has worked with children and young adults with Dravet syndrome for many years, I have witnessed first-hand the negative effect this condition has on quality of life for both patients and their loved ones," said Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy Program at the University of Leuven Hospitals and lead author of the article. "Currently, there are no available therapies that are able to provide lasting control over seizures for the vast majority of patients. The Dravet syndrome community desperately needs new treatment options that provide durable seizure control."
About the Survey
The Dravet syndrome caregiver survey (DISCUSS), was the largest survey ever conducted with caregivers of children with Dravet syndrome. DISCUSS was an online international cross-sectional study that sought to determine the social and financial impact of Dravet syndrome on patient and their caregivers and explore healthcare resource utilization associated with its current management. The survey was available in 12 languages (English, Spanish, Portuguese, French, Dutch, German, Italian, Polish, Croatian, and Romanian, Latin American Spanish and Brazilian Portuguese) and completed by 584 caregivers, of which over 92 percent lived in Europe.
Participants were recruited through email invitations to approximately 1,000 members of European patient advocacy groups associated with the Dravet Syndrome European Federation (DSEF) as well as through related internet based sources (Facebook and Twitter).
About the Dravet Syndrome European Federation
Dravet Syndrome European Federation (DSEF) is a federation of 15 European Dravet syndrome patient organizations aiming to improve the quality of life of patients and caregivers, promote research and knowledge exchange around Dravet syndrome, raise funds for medical and social research and raise disease awareness. www.dravet.eu
Aggregated DISCUSS survey results are available to the Dravet community for research purposes. Patient organizations, researchers, physicians, and industry can request access to the data via the DSEF. The DSEF board and their data management committee will consider any request for access where the proposed use of the data is of benefit to the Dravet community.
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
Dravet Syndrome European Federation Contact:
Isabella BRAMBILLA, President - +393356399693
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Media: David Polk
Senior Media Relations Strategist, INC Research/inVentivHealth
310-309-1029 | firstname.lastname@example.org
1. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52(Suppl. 2): 3-9.
2. Jensen MP, Brunklaus A, Dorris L, et al. The humanistic and economic burden of Dravet. Epilepsy Behav 2017; 70: 104-9.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zogenix, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41 | Pressemelding
TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of
eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30 | Pressemelding
SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with
Marcus Hiles - Texas Takes #1 Four Years in a Row in America's Top States for Business19.7.2018 23:39 | Pressemelding
DALLAS, July 19, 2018 (GLOBE NEWSWIRE) -- The future business scene in Texas is looking brighter than ever as the state continues to hold its place as a national leader. Growth is spreading across areas such as North Texas, Houston and San Antonio with businesses quickly expanding their operations in the state that offers some of the best in business-friendly climates and overall growth potential. Tapping into the market recently are global leaders such as Toyota, Liberty Mutual and JP Morgan who have taken advantage of the state's increasing network of commercial properties, workforce and business resources. Named by CNBC for the fourth consecutive year as America's Top State for Business, Texas scored above all 50 states on overall business competitiveness. With the business hub building on its role as a national leader for the past decade, this top rank title reflects the progress Texas has made in cementing its place in the global economy. "This national recognition comes without s
Second Quarter 2018 Results Conference Call19.7.2018 21:34 | Pressemelding
AURORA, Ontario, July 19, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) SECOND QUARTER 2018 RESULTS CONFERENCE CALL WEDNESDAY - AUGUST 8th, 2018 7:30 AM ET DIAL IN NUMBERS North America Toll Free: International Toll: Webcast: 1-888-223-4641 1-416-981-9080 www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until August 15, 2018 North America Toll Free: International Toll: Reservation No.: 1-800-558-5253 1-416-626-4100 21892829 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations email@example.com, 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations firstname.lastname@example.org, 905-726-7108 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originali
Uganda National Airlines Company Limited Signs Firm Order for Four Bombardier CRJ900 Aircraft19.7.2018 18:36 | Pressemelding
First operator of the new CRJ Series ATMOSPHÈRE cabin in Africa MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that it has signed a firm order for four new CRJ900 regional jets with Uganda National Airlines Company. Based on the list price for the CRJ900 aircraft, the firm order is valued at approximately US$190 million. "We congratulate the Government of Uganda for the revival of its national flag carrier, and are thrilled that the new airline has selected Bombardier and the CRJ900 regional jets for its upcoming debut," said Jean-Paul Boutibou, Vice President, Sales, Middle-East and Africa, Bombardier Commercial Aircraft. "Recognized for its superior economics and efficiency, the CRJ Series aircraft have enabled airlines worldwide to serve communities with better connectivity, and we look forward to supporting the development of Uganda's regional air travel with these CRJ900 regional jets." Uganda Airlines will operate the CRJ900 in dual-cla
CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology19.7.2018 15:03 | Pressemelding
"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies" SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL). The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models wil
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom